Top Medical News
Which PCI strategy is best for reducing cardiovascular events?
11 hours ago
Compared with intravascular imaging-guided and functionally guided percutaneous coronary intervention (PCI), angiography-guided PCI has consistently resulted in worse cardiovascular outcomes, a study has shown.
Myeloma patients may benefit from mezigdomide-dexamethasone doublet
Audrey Abella, 13 hours ago
In a study evaluating heavily pretreated patients with relapsed and refractory multiple myeloma (R/R MM), the combination of mezigdomide and dexamethasone showed promising preliminary efficacy, with myelosuppression and infection as primary toxicities.
Photoreceptor thinning linked to genetic AMD susceptibility in Asians
Jairia Dela Cruz, 17 hours ago
Thinner photoreceptor layers in the central macula appear indicative of genetic predisposition to age-related macular degeneration (AMD) in healthy Asians, as shown in a study from Singapore.
Dr Tan Toh Lick shares his insights on gestational diabetes
A diet rich in cholesterol during early pregnancy and genetic variations of cholesterol metabolism genes both contribute to the risk of gestational diabetes mellitus (GDM), suggests a study.
Lower leg brace helps reduce pain in medial tibial stress syndrome
Stephen Padilla, Yesterday
A pilot run for a lower leg brace designed for patients with medial tibial stress syndrome (MTSS) has shown a decrease in MTSS symptoms from 5 weeks up to over 6 months, with a lower recurrence rate, compared with placebo.
Alanine tied to diabetes, BP, lipid profile but not CAD
Plasma alanine or factors affecting alanine appear to contribute to an increased risk of diabetes, higher blood glucose, low-density lipoprotein cholesterol (LDL-C), and blood pressure (BP), but not coronary artery disease (CAD), reports a study.
Concizumab holds promise for patients with haemophilia A or B with inhibitors
Audrey Abella, Yesterday
In patients with haemophilia A (PwHA) or B (PwHB) with inhibitors, annualized bleeding rate (ABR) was lower with daily subcutaneous (SC) concizumab prophylaxis than with on-demand treatment, findings from the phase IIIa explorer7 trial have shown.
Special Reports
Breaking ground in migraine management: First Consensus Guidelines from the Headache Society of Singapore
06 Dec 2023
In a pioneering effort, the Headache Society of Singapore (HSS) has released the first edition of consensus guidelines focusing on the approach to headache disorders and management of migraine. Amid a rapidly growing array of therapeutic options, standardizing treatment approaches is crucial. These guidelines provide a pivotal resource for healthcare professionals navigating the complex landscape of headache disorders, with a special focus on migraine management in adults.
Strategies to Improve Vaccine Confidence
01 Dec 2023
Professor Heidi Larson, anthropologist and the founding director of The Vaccine Confidence Project, discusses the current state of vaccination worldwide and factors influencing vaccine uptake. Additionally, she advocates shift from using the phrase “vaccine hesitancy” when discussing challenges faced in vaccination to “vaccine confidence”. This enables vaccine confidence to be discussed in a positive light.
Optimisation of glycemic control with empagliflozin/linagliptin combination in a patient with type 2 diabetes mellitus uncont
30 Nov 2023
Data has demonstrated the efficiency of utilizing a combination of empagliflozin and linagliptin to effectively manage glycemic levels in patients with Type 2 diabetes (T2D) who are uncontrolled on metformin. In this retrospective analysis, we examine the combination of empagliflozin and linagliptin added to existing combination of multiple glucose-lowering medications sans insulin, which revealed significant improvements in both glycemic and cardio-renal outcomes for adults with T2D. This combination therapy was well-tolerated and showed promising clinical effectiveness when used in combination with commonly prescribed antidiabetic drugs for patients with inadequately controlled diabetes.

Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
Starting JAK inhibitors in the Asian population based on real-world experience
14 Nov 2023
Dermatologists from Asia shared their clinical experience on the use of Janus kinase (JAK) inhibitors in atopic dermatitis (AD) and discussed approaches towards shared patient and doctor decision-making for treatment with JAK inhibitors. Dr Mark Tang (Mount Alvernia Hospital, Singapore) chaired the virtual meeting, which was attended by local dermatologists.
A closer look at ceftazidime-avibactam in real-world settings
07 Nov 2023

Antibiotic misuse and overuse fuel mutations in bacteria, leading to drug-resistant “superbugs,” with terrifying aftermath. Without intervention, antimicrobial resistance could cause 10 million deaths annually by 2050.

Every year, from November 18–24, the World Antimicrobial Awareness Week highlights these risks and promotes innovative treatments, enhanced surveillance, and best-practice sharing among clinicians. This article offers insights on the use of the fixed-dose combination antibiotic ceftazidime-avibactam in daily hospital settings.

New study unlocks rimegepant benefits for acute migraine
06 Nov 2023

A landmark study conducted in China and South Korea has demonstrated the effectiveness and safety of rimegepant – a groundbreaking orally administered calcitonin gene-related peptide (CGRP) antagonist – for the acute treatment of migraine among adults. [Lancet Neurol 2023;22:476-484] This phase III, double-blind, randomized, placebo-controlled trial marks the first clinical study of a gepant for migraine in China and South Korea, offering promising insights into migraine management.

Effective management of type 2 diabetes mellitus with a combination of metformin and empagliflozin in a patient with metaboli
01 Nov 2023
Metabolic Syndrome (MS) is linked to insulin resistance and a combination of five medical conditions that increase the risk of developing atherosclerotic cardiovascular disease (ASCVD). Obesity is independently associated with an increased incidence of diabetes mellitus, hypertension, hyperlipidemia, cardiovascular disease (CVD), and certain cancers. Early CVD protection is crucial in MS patients with Type 2 diabetes (T2DM). The use of empagliflozin/metformin for managing T2DM in MS improved fasting blood glucose levels and HbA1c, demonstrating the effectiveness of this combination in both ASCVD and CVD risk factors patients.

Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
Conference Reports
Expert shares lessons from COVID-19
Elvira Manzano, 06 Dec 2023
The world is out of the pandemic, but several subvariants of Omicron are still evolving, says Dr Adrian Chan, respiratory physician and intensivist at Mount Elizabeth Novena Hospital, Singapore, during his talk at APSR 2023.
Remibrutinib improves CSU symptoms in phase III trials
Elvira Manzano, 05 Dec 2023
Treatment with the investigational, oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib improves symptoms in patients with chronic spontaneous urticaria (CSU) inadequately controlled on antihistamines, the phase III REMIX-1 and -2 studies have shown.
Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients
Audrey Abella, 05 Dec 2023
In the phase III REMAIN-2 trial, add-on recaticimab – a novel, long-acting anti-PCSK9 monoclonal antibody (mAb) – led to reductions in bad cholesterol and other lipids in patients with non-familial hypercholesterolaemia (non-FH) and mixed hyperlipidaemia inadequately controlled on background statin therapy.
Intermittent dosing of dual HIV therapy for HIV disappoints in DUETTO trial
Elvira Manzano, 05 Dec 2023
Four-day-a-week dosing of dual therapy for HIV performs similarly to daily doses in terms of sustaining viral suppression in the DUETTO trial. However, virological failure (VF) and drug resistance rates were higher with the 4-day/week dosing regimen.
Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC
Elaine Soliven, 01 Dec 2023

Treatment with seladelpar significantly improves serum markers of cholestasis, including alkaline phosphatase (ALP) and total bilirubin (TB), and reduces pruritus in patients with primary biliary cholangitis (PBC) who are at risk of disease progression, according to the RESPONSE trial presented at AASLD 2023.

Dupilumab reduces SCS use in type 2 asthma regardless of prior exacerbations
Elaine Soliven, 30 Nov 2023

Treatment with dupilumab reduces the use of systemic corticosteroids (SCS) in children with moderate-to-severe asthma, regardless of exacerbation history, according to a post hoc analysis of the VOYAGE and EXCURSION trials presented at APSR 2023.

Simplified, tailored treatment for asthma improves patient outcomes
Audrey Abella, 29 Nov 2023
Asthma is a highly prevalent disease that can affect anybody regardless of age, race, and location. The overall burden of asthma remains severe. Despite the range of available therapies and well-established guidelines, there remains a significant unmet need in the management of asthma. [BMC Public Health 2012;12:860; Respir Res 2023;24:169; Eur Respir J 2014;43:343-373]